Alessandro Riva, MD, joins a long list of leadership departures from Gilead. The company also saw its CEO John Milligan, Chairman John Martin, R&D chief Norbert Bischofberger and CMO Andrew Cheng exit the company.
Dr. Riva is shifting to lead a new biotech spinoff from India’s Glenmark, which will be based in the U.S. The spinoff will focus on oncology and T-cell therapies, according to EndPoints News.
Dr. Riva joined Gilead in January 2017 and will remain with the company until the end of March.
More articles on pharmacy:
Viewpoint: It’s time for pharma to have its ‘tobacco moment’
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Drugmakers are treating patients, providers ‘like piggy banks,’ AHA chief says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
